Results 31 to 40 of about 14,507 (219)

Biomarkers of Inflammation and Fibrosis in Kawasaki Disease Patients Years After Initial Presentation With Low Ejection Fraction. [PDF]

, 2020
Background Coronary artery aneurysms and myocarditis are well-recognized complications of Kawasaki disease (KD) but no systematic evaluation of the consequences of myocarditis has been performed in the subset presenting with low ejection fraction (EF ...
Burns, Jane C, He, Feng, Hoshino, Shinsuke, Jain, Sonia, Shimizu, Chisato, Tremoulet, Adriana H   +5 more
core  

Effects of iron chelation therapy on the clinical course of aceruloplasminemia: an analysis of aggregated case reports

Orphanet Journal of Rare Diseases, 2020
Background Aceruloplasminemia is a rare genetic iron overload disorder, characterized by progressive neurological manifestations. The effects of iron chelation on neurological outcomes have only been described in case studies, and are inconsistent ...
Lena H. P. Vroegindeweij, Agnita J. W. Boon, J. H. Paul Wilson, Janneke G. Langendonk   +3 more
doaj   +1 more source

Identification of novel UROS mutations in a patient with congenital erythropoietic porphyria and efficient treatment by phlebotomy

Molecular Genetics and Metabolism Reports, 2021
Congenital erythropoietic porphyria (CEP) is an autosomal recessive disorder of the heme biosynthetic pathway that is characterized by uroporphyrinogen III synthase (UROS) deficiency and the accumulation of non-physiological isomer I porphyrins.
Jean-Marc Blouin, Cécile Ged, Ganeko Bernardo-Seisdedos, Txomin Cabantous, Benoît Pinson, Antoine Poli, Hervé Puy, Oscar Millet, Laurent Gouya, Fanny Morice-Picard, Emmanuel Richard   +10 more
doaj   +1 more source

CareerAdvance® Implementation Study Findings through FY 2018 [PDF]

, 2018
This report examines the implementation of the third year of HPOG II services in a five-year grant cycle, including post-HPOG sustainability planning for CareerAdvance®.
Anderson, Amy, Juniper, Cynthia, King, Christopher T.   +2 more
core   +2 more sources

A Study of Indications, Clinical Applications, and Effects of Therapeutic Phlebotomy at a Tertiary Care Hospital Navi Mumbai

Global Journal of Transfusion Medicine
Background and Objectives: The removal of blood from the body is known as phlebotomy, venesection, or bloodletting. Therapeutic phlebotomy is the preferred treatment for blood disorders where removing red blood cells or serum iron is the most effective ...
Sonal Suresh Gupta, Shweta Wasudeo Dhote, Shubhangi Lad, Damayanti Radhashyam Dey   +3 more
doaj   +1 more source

Biomarkers for Huntington's disease: an update [PDF]

, 2012
Huntington's disease (HD) is a devastating autosomal-dominant neurodegenerative condition caused by a CAG repeat expansion in the gene encoding huntingtin which is characterised by progressive motor impairment, cognitive decline and neuropsychiatric ...
Scahill, RI, Tabrizi, SJ, Wild, EJ
core   +1 more source

Microfluidic flow chambers using reconstituted blood to model hemostasis and platelet transfusion in vitro [PDF]

, 2016
Blood platelets prepared for transfusion gradually lose hemostatic function during storage. Platelet function can be investigated using a variety of (indirect) in vitro experiments, but none of these is as comprehensive as microfluidic flow chambers.
Compernolle, Veerle, Devloo, Rosalie, Feys, Hendrik, Van Aelst, Britt, Vandekerckhove, Philippe   +4 more
core   +2 more sources

Testosterone therapy-induced erythrocytosis: can phlebotomy be justified?

Endocrine Connections
Erythrocytosis, or elevated hematocrit, is a common side effect of testosterone therapy (TTh) in male hypogonadism. Testosterone stimulates erythropoiesis through an initial rise in erythropoietin (EPO), the establishment of a new EPO/hemoglobin ‘set ...
Peter Bond, Tijs Verdegaal, Diederik L Smit   +2 more
doaj   +1 more source

Analysis of Therapeutic Phlebotomy in Patients of Polycythemia: A Single Center Study

Journal of Islamabad Medical & Dental College, 2023
Introduction: Polycythemia is increased red cell mass according to age and sex of the individual. It could be primary (Polycythemia Vera), or secondary, due to chronic hypoxia or increased erythropoietic drive. Polycythemia is managed with therapeutic phlebotomy along with treating the underlying cause if determined.
Nosheena Noreen, Syeda Wajeeha Jalil, Rabeea Irfan, Farah Hanif   +3 more
openaire   +1 more source

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]

, 2016
The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core   +2 more sources